NASDAQ: CRME TSX: COM
VANCOUVER, May 19 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the waiting period under the Hart-Scott-Rodino Act for the collaboration and license agreement with Merck & Co., Inc. and a Merck affiliate for development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation, has expired, and the agreement is now effective.
Under terms of the agreement, effectiveness of the agreement triggers an initial payment of US$60 million to Cardiome from Merck. Further terms of the agreement are outlined in our press release dated April 8, 2009.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such
|SOURCE Cardiome Pharma Corp.|
Copyright©2009 PR Newswire.
All rights reserved